Mikhail Blagosklonny: A Passionate Advocate for Rapamycin

Mikhail Blagosklonny, a Russian scientist, remains one the most ardent advocates of the anti-aging drug called rapamycin. He is a native of St. Petersburg and holds an M.D. in internal medicine as well as a PhD in experimental medicine and cardiology from First Pavlov State Medical University of St. Peterburg. His working experience has added in no small measure to his verse knowledge about cancer and anti-aging therapies having spent time at New York Medical College as an associate professor,Ordway Research Institute as a senior scientist and Roswell Park Cancer Institute where he is currently a professor of oncology since 2009.

Blagosklonny has been carrying out researches on finding new and effective therapies for cancer for several years. He never gave up; he realized in the early 2000s that rapamycin ability to slow tumor growth can also be effective in slowing the aging process. His conviction about the safety and qualities of rapamycin grew to the extend that he tried it himself. When asked if rapamycin is dangerous to human health, he disagree by pointing to the combination of overeating, smoking and driving without belt as posting more danger than rapamycin.To him, rapamycin does as much good as exercising.

Blagosklonny took time to read through all reported side effects of rapamycin and aspirin. He found the later having more side effects. He concluded by saying that rapamycin is yet to show any serious side effects since its approval over 15 years ago.

Mikhail Blagosklonny’s exceptional editorial skills help in propagating his in-dept knowledge about cancer and the adverse effect of aging as well as how these health abnormalities can be curbed. He has over 250 articles, book chapters and reviews to his credit.

A number of top medical journeys and magazine have him on their editorial board.Currently, he occupies the office of the editor-in-chief for Aging, Oncotarget and Cell Cycle. He is an associate editor to Cancer Biology & Therapy. Also, he is on the editorial board of Cell Death & Differentiation.

Many people would have missed out of the good rapamycin does if people with high medical pedigree like Mikhail Blagosklonny did not give their support passionately.

View Mikhail’s profile on Google Scholar.